359 related articles for article (PubMed ID: 18725978)
1. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Østenstad B; Lundgren S; Berge EO; Risberg T; Mjaaland I; Maehle L; Engebretsen LF; Lillehaug JR; Lønning PE
PLoS One; 2008 Aug; 3(8):e3062. PubMed ID: 18725978
[TBL] [Abstract][Full Text] [Related]
2. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
[TBL] [Abstract][Full Text] [Related]
3. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Skjønsberg G; Aas T; Schlichting E; Fjösne HE; Nysted A; Lillehaug JR; Lønning PE
PLoS One; 2011 Apr; 6(4):e19249. PubMed ID: 21556366
[TBL] [Abstract][Full Text] [Related]
4. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
5. Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.
Knappskog S; Berge EO; Chrisanthar R; Geisler S; Staalesen V; Leirvaag B; Yndestad S; de Faveri E; Karlsen BO; Wedge DC; Akslen LA; Lilleng PK; Løkkevik E; Lundgren S; Østenstad B; Risberg T; Mjaaland I; Aas T; Lønning PE
Mol Oncol; 2015 Oct; 9(8):1553-64. PubMed ID: 26004085
[TBL] [Abstract][Full Text] [Related]
6. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
7. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
[TBL] [Abstract][Full Text] [Related]
8. P53 and its molecular basis to chemoresistance in breast cancer.
Knappskog S; Lønning PE
Expert Opin Ther Targets; 2012 Mar; 16 Suppl 1():S23-30. PubMed ID: 22313396
[TBL] [Abstract][Full Text] [Related]
9. Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations.
Barekati Z; Radpour R; Kohler C; Zhang B; Toniolo P; Lenner P; Lv Q; Zheng H; Zhong XY
Hum Mol Genet; 2010 Aug; 19(15):2936-46. PubMed ID: 20466735
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.
Caca K; Feisthammel J; Klee K; Tannapfel A; Witzigmann H; Wittekind C; Mössner J; Berr F
Int J Cancer; 2002 Feb; 97(4):481-8. PubMed ID: 11802210
[TBL] [Abstract][Full Text] [Related]
11. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.
Pennington KP; Walsh T; Lee M; Pennil C; Novetsky AP; Agnew KJ; Thornton A; Garcia R; Mutch D; King MC; Goodfellow P; Swisher EM
Cancer; 2013 Jan; 119(2):332-8. PubMed ID: 22811390
[TBL] [Abstract][Full Text] [Related]
12. Wip1 over-expression correlated with TP53/p14(ARF) pathway disruption in human astrocytomas.
Wang P; Rao J; Yang H; Zhao H; Yang L
J Surg Oncol; 2011 Nov; 104(6):679-84. PubMed ID: 21695702
[TBL] [Abstract][Full Text] [Related]
13. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
14. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
Zheng L; Wang F; Qian C; Neumann RM; Cheville JC; Tindall DJ; Liu W
Hum Mutat; 2006 Oct; 27(10):1062-3. PubMed ID: 16941491
[TBL] [Abstract][Full Text] [Related]
15. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
[TBL] [Abstract][Full Text] [Related]
16. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.
Smid M; Schmidt MK; Prager-van der Smissen WJC; Ruigrok-Ritstier K; Schreurs MAC; Cornelissen S; Garcia AM; Broeks A; Timmermans AM; Trapman-Jansen AMAC; Collée JM; Adank MA; Hooning MJ; Martens JWM; Hollestelle A
Breast Cancer Res; 2023 May; 25(1):53. PubMed ID: 37161532
[TBL] [Abstract][Full Text] [Related]
18. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
Nakamura Y; Oshima K; Naoi Y; Nakayama T; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Jul; 134(1):229-36. PubMed ID: 22315133
[TBL] [Abstract][Full Text] [Related]
19. Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines.
Wasielewski M; Hanifi-Moghaddam P; Hollestelle A; Merajver SD; van den Ouweland A; Klijn JG; Ethier SP; Schutte M
Breast Cancer Res Treat; 2009 Jan; 113(2):285-91. PubMed ID: 18297428
[TBL] [Abstract][Full Text] [Related]
20. CHEK2 gene alterations independently increase the risk of death from breast cancer in Bulgarian patients.
Angelova SG; Krasteva ME; Gospodinova ZI; Georgieva EI
Neoplasma; 2012; 59(6):622-30. PubMed ID: 22862163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
